Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Interest & Investment Income: 2014-2024

Historic Interest & Investment Income for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to $21.3 million.

  • Spyre Therapeutics' Interest & Investment Income rose 3.76% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 19.63%. This contributed to the annual value of $21.3 million for FY2024, which is 246.71% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Interest & Investment Income of $21.3 million as of FY2024, which was up 246.71% from $6.1 million recorded in FY2023.
  • Over the past 5 years, Spyre Therapeutics' Interest & Investment Income peaked at $21.3 million during FY2024, and registered a low of $111,000 during FY2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $6.1 million (2023), whereas its average is $9.4 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first slumped by 81.28% in 2021, then skyrocketed by 654.05% in 2022.
  • Spyre Therapeutics' Interest & Investment Income (Yearly) stood at $593,000 in 2020, then slumped by 81.28% to $111,000 in 2021, then spiked by 654.05% to $837,000 in 2022, then soared by 634.41% to $6.1 million in 2023, then soared by 246.71% to $21.3 million in 2024.